Earlier this month, pharmacy benefit managers (PBMs) were called before the Senate Finance Committee to answer questions about how their businesses impact drug prices for Americans. While the executives deflected criticism and pointed to issues like legal challenges to biosimilars as playing a key role in keeping drug prices high, lawmakers and officials are taking steps to rein in PBMs.
Earlier this month, pharmacy benefit managers (PBMs) were called before the Senate Finance Committee to answer questions about how their businesses impact drug prices for Americans. While the executives deflected criticism and pointed to issues like legal challenges to biosimilars as playing a key role in keeping drug prices high, lawmakers and officials are taking steps to rein in PBMs.
This week, Representative Peter Welch, D-Vermont, announced 2 new bills targeting PBMs’ practices. The first bill would prevent PBMs from imposing retroactive fees on pharmacy drug sales, while the second would prohibit PBMs from excluding small, independent pharmacies from joining preferred pharmacy networks that fill prescriptions for Medicare beneficiaries.
According to Welch, these bills will address 2 significant threats to local pharmacies to help ensure fair competition and keep small pharmacies in business.
Separately, Dave Yost, attorney general of the state of Ohio, has filed a lawsuit against the PBM OptumRx.
According to the complaint, filed in Franklin County, Ohio, OptumRx, which served as the Ohio Bureau of Workers Compensation (BWC)’s PBM from 2009 to October 2018, breached its contract with the state. The breaches alleged include failure to provide a guaranteed discount on generic drug prices, resulting in nearly $16 million in damages, and making misrepresentations to the state in order to be selected as its PBM.
The complaint explains that, in 2009, the BWC sought to enter into a pass-through contract with a PBM, in which the selected PBM would receive only administrative fees for its transactions conducted on behalf of the BWC. In such an arrangement, the PBM would be obligated to pass through the costs of drugs without markup, eliminating the possibility of spread pricing or rebates.
“Deprived of the opportunity to ramp up profits,” says the complaint, the PBM “found another way to add to its bottom line at the expense of BWC—by failing to provide the promised and agreed to pricing discounts for drugs purchased by BWC claimants.”
The complaint explains that OptumRx did not comply with its contractual duty to provide minimum average discounts of 74% off average sales price to BWC, as determined by an independent consultant hired to examine compliance. When BWC threatened to terminate the contract, OptumRx amended the contract. According to the BWC, the PBM then failed to meet its obligations under the amendment. Later, the PBM also increased the prices of drugs without explanation.
“When challenged by BWC about its failure to abide by the [agreement],” reads the complaint, OptumRx “tellingly, did not deny BWC’s obligations…instead Defendant admitted it had breached the agreement.”
Ohio is seeking a trial by jury and has asked for compensatory damages, punitive damages, all costs of litigation, and other relief the court deems to be appropriate.
In a statement, Yost said that the state’s review of PBM practices is ongoing and called this lawsuit “the first raindrops” in a coming storm.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.